| Population 2015 |
127 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
2.6 |
(2.6–2.7) |
2.1 |
(2–2.1) |
| Mortality (HIV+TB only) |
0.51 |
(0.03–1.7) |
0.4 |
(0.02–1.3) |
| Incidence (includes HIV+TB) |
27 |
(22–32) |
21 |
(17–25) |
| Incidence (HIV+TB only) |
3 |
(1.9–4.3) |
2.3 |
(1.5–3.4) |
| Incidence (MDR/RR-TB)** |
0.91 |
(0.75–1.1) |
0.72 |
(0.59–0.87) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
1.2 |
(0.64–1.7) |
9 |
(6–12) |
10 |
(6.6–14) |
| Males |
1.3 |
(0.84–1.7) |
15 |
(12–18) |
16 |
(12–20) |
| Total |
2.4 |
(1.8–3.1) |
24 |
(21–27) |
27 |
(22–32) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
22 294 |
| Total new and relapse |
21 600 |
| - % tested with rapid diagnostics at time of diagnosis |
1% |
| - % with known HIV status |
89% |
| - % pulmonary |
81% |
| - % bacteriologically confirmed among pulmonary |
83% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
81% (68–99) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.12 (0.08–0.16) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
2 188 |
11% |
| - on antiretroviral therapy |
2 120 |
97% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
610
(540–670) |
| Estimated % of TB cases with MDR/RR-TB |
2.6% (2.3–2.9) |
11% (9.2–13) |
|
| % notified tested for rifampicin resistance |
2% |
35% |
1 072 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
51 |
| Laboratory-confirmed cases |
MDR/RR-TB: 158, XDR-TB: 2 |
| Patients started on treatment **** |
MDR/RR-TB: 146, XDR-TB: 5 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
80% |
21 193 |
| Previously treated cases, excluding relapse, registered in 2014 |
53% |
685 |
| HIV-positive TB cases, all types, registered in 2014 |
48% |
1 318 |
| MDR/RR-TB cases started on second-line treatment in 2013 |
60% |
167 |
| XDR-TB cases started on second-line treatment in 2013 |
75% |
4 |
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
19% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
100% (100–100) |
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
19 |
| Funding source: 100% domestic, 0% international, 0% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |